Us Bancorp \De\ Prelude Therapeutics Inc Transaction History

Us Bancorp \De\

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$4.0 - $7.55 $2,424 - $4,575	-606 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$6.9 - $13.22 $2,925 - $5,605	424 Added 232.97%	606 $4,000
Q4 2021 Feb 11, 2022	BUY	$11.89 - $31.74 $285 - $761	24 Added 15.19%	182 $2,000
Q3 2021 Nov 10, 2021	BUY	$25.78 - $38.65 $4,073 - $6,106	158 New	158 $5,000
Q1 2021 Apr 28, 2021	SELL	$39.27 - $91.68 $706 - $1,650	-18 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$28.81 - $88.94 $518 - $1,600	18 New	18 $1,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $41.8M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.